Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) inhibitors, including monoclonal antibodies and small molecules, show significant antitumor activity.
• These inhibitors potentiate conventional therapies, acting as chemosensitizers and reversing drug resistance in preclinical models.
• Clinical trials suggest potential chemosensitization in head and neck and lung cancers, pending Phase III confirmation.

Purpose of the Study:

• To explore the largely uninvestigated mechanisms of acquired resistance to EGFR inhibitors.
• To propose alternative combination therapies to circumvent and delay the development of resistance.

Main Methods:

• Review of preclinical and clinical literature on EGFR inhibitors.
• Analysis of potential molecular mechanisms underlying acquired resistance.
• Synthesis of data to suggest novel therapeutic strategies.

Main Results:

• Acquired resistance to EGFR inhibitors is a significant clinical challenge, mirroring resistance seen with other anticancer drugs.
• Several potential mechanisms can lead to the development of resistance to EGFR-targeting drugs.
• The development of resistance to EGFR inhibitors remains an under-explored area.

Conclusions:

• Understanding acquired resistance mechanisms is crucial for effective EGFR inhibitor therapy.
• Alternative combination strategies are necessary to overcome and delay resistance.
• Further research into resistance mechanisms and novel therapeutic combinations is warranted.